291 Campus Drive
Li Ka Shing Learning and Knowledge Center
Stanford, CA 94305-5101
United States
Hodgkin lymphoma, Brentuximab vedotin, residual node radiation, response adapted therapy, pediatric, high-risk, frontline trial